Intercept Pharmaceuticals: Q2 Earnings Insights

  Intercept Pharmaceuticals (NASDAQ:ICPT) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

 

Intercept Pharmaceuticals (NASDAQ:ICPT) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:00 AM.

Here’s what investors need to know about the announcement.

Earnings

Intercept Pharmaceuticals missed estimated earnings by 525.0%, reporting an EPS of $-0.25 versus an estimate of $-0.04.

Revenue was down $24.82 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.32 which was followed by a 1.63% drop in the share price the next day.

Here’s a look at Intercept Pharmaceuticals’s past performance:

 

Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021
EPS Estimate -0.90 -1.10 -1.09 -1.21
EPS Actual -0.58 -1.23 -0.63 -0.33
Revenue Estimate 90.49M 92.38M 83.02M 82.95M
Revenue Actual 88.58M 92.40M 92.83M 96.58M

To track all earnings releases for Intercept Pharmaceuticals visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Earnings Outlook For Cisco Systems

Cisco Systems (NASDAQ:CSCO) is set to give its latest quarterly earnings report on Wednesday, 2022-11-16. Here's what investors need to know before the announcement. Analysts estimate that Cisco Systems will report an earnings per share (EPS) of $0.84.

CSCO

Read More

VBL Therapeutics Announces Completion Of Enrollment In Oval Phase 3 Registration-enabling Trial Of Ofra-Vec In Ovarian Cancer And Unanimous Recommendation By Independent Data Safety Monitoring Committee To Continue Study As Planned

VBL Therapeutics (NASDAQ:VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today

VBLT